Replies to post #8442 on RespireRx Pharmaceuticals Inc (fka RSPI)

[rusbrn]

<Cortex aims to start a Phase IIb study in 2H07
with CX717 in ADHD, pending the acceptance of an IND including the request to test higher doses of CX717. This IND
has been submitted to the FDA�s Psychiatric Products Division and Cortex expects a decision in September 2007. >
Apparently some have not read post #8423
Russ.